Changes in plasma vascular endothelial growth factor receptor 2 and alpha fetal protein after sorafenib administra-tion for HBV related hepatocellular carcinoma
YANG Shuo
ZHANG Yunhui
SHI Min
LI Fengyi
CHEN Weiwei
ZHOU Zhiping
Abstract：Objective To investigate the changes of serum of vascular endothelial growth factor receptor 2 ( VEGFR-2) and alpha fetal protein (AFP) levels for using sorafenib in the treatment of HBV related hepatocellular carcinoma (HCC). Methods 46 patients who meet the diagnostic criteria of Barcelona in the late stage of HBV related HCC patients were select-ed and divided into 2 groups, 23 cases in each group , the control group were treated with anti HBV , anti symptomatic , sup-portive and other conventional treatment , the treatment group were treated with sorafenib 400 mg orally on the basis of conven-tional therapy, 2 times a day.6 weeks as 1 observation period.Serum VEGFR-2 and AFP levels were observed in both of the 2 groups.Results Control group’s VEGFR-2’s level in before treatment (8 603.2 pg /ml ±573.4 pg /ml) and after treatment (8 303.1 pg /ml ±527.7 pg /ml) did not show significant changes ( P >0.05); treatment group’s after treat-ment’s level (6 313.8 pg /ml ±559.9 pg /ml) were significantly lower than those before treatment (8 401.1 pg/ml ± 414.6 pg/ml), the difference has statistical significance ( P <0.05).The treatment group’s index was decreased more than that of control group ( P <0.05).The control group and the treatment group ’ s AFP level before treatment were 100.8 (25.0,1 925.1) pg /ml and 89.2 (21.7, 1 567.2) pg /ml, after treatment were 103.7 (18.5.2 083.2) pg/ml and 78.4 (21.6, 684.3) pg/ml, respectively, before and after treatment, AFP had no obvious change in both of the two groups ( P >0.05).VEGFR 2 and AFP level had no correlation( r =-0.337, P =0.048).Conclusion Sorafenib can decrease VEG-FR 2 in patients with HCC , it has certain significance to the clinical treatment of liver cancer .
Keywords：SorafenibHepatitis BHepatacocellular carcinomaVascular endothelial growth factor 2Alpha fetal protein
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 936-938,943 )